Abstract Safe and efficacious vectors able to carry large or several transgenes are of key importance for gene therapy. Human artificial chromosomes can fulfil this essential requirement; moreover, they do not integrate into the host genome. However, drawbacks such as the low efficiency of chromosome transfer and their relatively complex engineering still limit their widespread use. In this article, I summarise the key steps that brought human artificial chromosomes into preclinical research for Duchenne muscular dystrophy, an X-linked, monogenic disorder. I will also review possible future pre-clinical and clinical perspectives for this technology.
iPS
Induced pluripotent stem (cells) MMCT Microcell-mediated chromosome transfer PEG Polyethylene glycol
Duchenne muscular dystrophy: a major challenge for gene therapy Duchenne muscular dystrophy (DMD) is among the most common human paediatric monogenic disorders, affecting up to 1/3500 male births. Almost 30 years have passed since the discovery that DMD was caused by mutations in the dystrophin gene on the X chromosome (Hoffman et al. 1987) . Dystrophin mutations cause progressive muscle degeneration, wasting and weakness. This results in loss of motility, respiratory and cardiac failure and, ultimately, death (Mercuri and Muntoni 2013) . No cure is currently available for DMD, and the search for possible therapies is challenging generations of clinicians and scientists. Nevertheless, several strategies are undergoing experimental testing, with some of them in promising phase II or III clinical trials (Benedetti et al. 2013) . Among these, gene replacement is still an attractive option in light of large deletions or mutations in critical domains of the protein that preclude the use of shorter functional versions of the dystrophin protein, such as those generated by antisense oligonucleotide-mediated exon skipping (Muntoni and Wood 2011; Benedetti et al. 2013) . Moreover, after years of assiduous research, gene therapy is now delivering excellent clinical results (Aiuti et al. 2009; Gaspar et al. 2011; Biffi et al. 2013 ). However, specific hurdles slowing down major progress in DMD gene therapy are as follows: (1) dystrophin is the largest human gene (2.4 Mb) with a complex transcriptional regulation (Muntoni et al. 2003) ; (2) even dystrophin full complementary DNA (cDNA) (14 kb) cannot be accommodated inside conventional vectors that allow stable gene expression in dividing and non-dividing cells; (3) the main tissue affected in DMD is skeletal muscle, which is also the most abundant tissue of the human body, and this means that the transgene needs to target a reasonable high number of nuclei to provide some efficacy; (4) increasing evidence shows exhaustion or dysfunction of dystrophic stem/progenitor cells, necessary for ex vivo gene therapy (Blau et al. 1983; Cohn et al. 2002; Sacco et al. 2010; Cassano et al. 2011; Kudryashova et al. 2012; Tedesco et al. 2012) ; and (5) the brain and heart are also affected in DMD, and this together with the widespread distribution of skeletal muscle poses additional hurdles for the delivery of the transgene.
Therefore, a large cargo vector with a safe and stable expression profile would be an ideal candidate to bypass most of the aforementioned limitations. In this review, I will summarise the evidence that brought human artificial chromosomes (HACs) into DMD gene therapy, analysing advantages and disadvantages of this platform for skeletal muscle repair and regeneration. I will not analyse previous and current use of HACs for pharmaceutical applications, animal transgenesis and cytogenetic studies, for which I redirect the reader to excellent reviews in other journals Kouprina et al. 2014) and in this special issue.
Too big to transfer, too much to fix
Initial attempts to transfer the entire dystrophin cDNA were based upon direct intra-muscular injection of cDNAs in mdx mice, which model DMD (Bulfield et al. 1984; Acsadi et al. 1991) . Although plasmids provided a proof-of-principle that transfer of the entire cDNA restores dystrophin in some myofibres, it was soon clear that delivery of the plasmid to all muscles would be a major challenge. Moreover, immunological issues related to direct DNA transfer into muscle added another layer of complexity to this strategy. Two possible options were available at this point: (1) to shorten the cDNA size, so that it could be inserted into a viral vector with more efficient transfer rate (although immunity, delivery and presence of functional skeletal muscle would still be issues), and (2) to use muscle stem cells as a "trojan horse" to transfer the whole gene to skeletal myofibres (gene and cell therapy). This last approach proved to be promising following seminal work of Partridge and colleagues in 1989, demonstrating generation of dystrophinpositive myofibres after normal donor myoblast transplantation in mdx mice (Partridge et al. 1989 ). However, when a similar approach was undertaken in human clinical trials, allogeneic myoblast transplantation showed safety but not functional clinical efficacy in DMD patients (Partridge 2002; Tedesco et al. 2010; Skuk and Tremblay 2014) . For this reason and to avoid immune-suppressive therapy for allogeneic transplants (reviewed in Maffioletti et al. 2014) , several groups turned their attention back to gene transfer in DMD, either directly into muscle or via ex vivo correction of dystrophic muscle stem/progenitor cells.
However, the choice of an ideal muscle stem cell candidate also posed some hurdles, as the limitations of myoblasts for systemic delivery redirected the attention of the muscle community towards alternative and nonconventional myogenic progenitors different from satellite cells/myoblasts (Benedetti et al. 2013) . One of these cell types, called mesoangioblast, was identified initially in the embryonic vessel wall of the dorsal aorta, and subsequently, its adult counterpart was identified in a subset of skeletal muscle pericytes (Minasi et al. 2002; Dellavalle et al. 2007 ). These cells have been shown to contribute also to normal skeletal muscle development . When delivered intra-muscularly or intra-arterially in dystrophic animal models mesoangioblasts ameliorated muscle morphology and function (reviewed in Benedetti et al. (2013) ). Based upon this pre-clinical evidence, a firstin-human clinical trial to test their safety has been recently completed in five Duchenne boys (EudraCT no. 2011-000176-33; www.clinicaltrialsregister.eu). This trial is based upon infusion of HLA-matched allogeneic donor pericytes/mesoangioblasts. The need to translate this strategy to an autologous setting prompted the search for a possible candidate vector for DMD therapy that would allow transfer of the entire dystrophin gene without the risk of insertional mutagenesis (Biasco et al. 2012 ).
Engineering human artificial chromosomes
An alternative approach to the "shortening" of a specific gene/cDNA to allow its accommodation into a vector is to increase the cargo capacity of the vector itself. This strategy would fit perfectly with the large size of dystrophin. To achieve this aim, Oshimura and his group pioneered the engineering of a HAC containing the entire dystrophin genetic locus (DYS-HAC) (Hoshiya et al. 2009 ).
HACs are exogenous mini-chromosomes generated either by a "bottom-up"/de novo strategy (Mandegar et al. 2011; Kononenko et al. 2014) or engineered by a "top-down approach" (engineered chromosomes) ). They remain episomal (i.e. not integrated) in the host genome and get replicated and segregated during mitosis as supernumerary minichromosomes. This prevents silencing of the transgene due to possible positional effect, interference with endogenous gene expression and, most importantly, cell transformation due to insertional mutagenesis.
A top-down approach was utilized to engineer the DYS-HAC (Hoshiya et al 2009) . Human chromosome 21 was "deconstructed" of all its endogenous genes and utilized as HAC "backbone" . In parallel, a fragment of the human X chromosome containing its short arm was transferred into the homologous recombinationproficient chicken DT40 cell line and a loxP cassette was targeted proximally to the human dystrophin locus. Distal endogenous X chromosome genes were removed by telomere-associated chromosome truncation. This modified X fragment was transferred into Chinese hamster ovary (CHO) cells containing the above HAC using a PEG fusionbased technique called microcell-mediated chromosome transfer (MMCT) (Fournier and Ruddle 1977; Uno et al. 2013) . As a result, the entire dystrophin 2.4-Mb genetic locus was cloned into the HAC vector by Cre-loxP-mediated chromosomal translocation. At this stage, the so-called DYS-HAC was ready to be tested and transferred to target cells. To this aim, the resulting CHO hybrids were expanded, characterized and enucleated to generate microcells for MMCT to target cells, which after DYS-HAC transfer in turn expanded under selection drugs and then screened for the presence of an episomal and stable HAC.
Stem/progenitor cells: HAC's troy horse
The first candidates to test the DYS-HAC were mouse embryonic stem cells, with whom trans-chromosomic mice expressing the different isoforms of human dystrophin were generated as a proof-of-principle of its function in vivo (Hoshiya et al. 2009 ). Even though the DYS-HAC was also transferred into human mesenchymal stem cells (Hoshiya et al. 2009 ), these cells have shown not to be an ideal candidate for the cell therapy of muscular dystrophy (Gang et al. 2009 ). To achieve this a i m , t h e D Y S -H A C w a s t r a n s f e r r e d i n t o mesoangioblasts isolated from mdx mice and the resulting genetically corrected cells were transplanted into dystrophic and immune-deficient scid/mdx mice, to avoid rejection caused by the presence of the human dystrophin and other HAC transgenes (e.g. GFP). Remarkably, transplanted animals showed morphological and functional amelioration of the dystrophic phenotype. This was the first evidence of HAC-mediated gene therapy strategy that resulted in a safe and efficacious outcome of a genetic disease .
In parallel, Kazuki, Oshimura and colleagues transferred the same DYS-HAC into induced pluripotent stem (iPS) cells derived from DMD patients (Kazuki et al. 2010 ) and the resulting iPS cells were also differentiated into pericyte/mesoangioblast-like myogenic progenitors, which correctly expressed human dystrophin (Tedesco et al. 2012 ). More recently, DYS-HACcorrected DMD iPS cells have also been successfully differentiated into cardiomyocytes, which correctly expressed the different dystrophin isoforms during the differentiation process (Zatti et al. 2014 ). We are currently focusing our efforts to extend the DYS-HACbased platform to human muscle-derived stem/ progenitor cells and to iPS cells generated and differentiated with novel and safer integration-free strategies. Notably, the use of tissue-derived progenitors requires one additional step necessary to extend cell proliferation to survive the clonal process of HAC transfer. To this aim, we have engineered muscle progenitors with excisable lentiviral vectors expressing immortalizing genes and safety/suicide cassettes in a reversible fashion, so that the cells will sustain expansion to numbers compatible with those necessary to treat a patient (i.e. in the range of 10 9 cells; Benedetti et al., in preparation) . In parallel, in case the isolation of muscle stem/progenitor cells results difficult from a muscle biopsy, myogenic progenitors can be derived from human iPS cells (Darabi et al. 2012; Goudenege et al. 2012; Tedesco et al. 2012; Borchin et al. 2013; Tanaka et al. 2013; Xu et al. 2013) .
Current challenges and future perspectives
HAC-based gene therapy promises to overcome space limitation issues of current vectors and the risk of mutagenesis following integration into host genome. This is particularly attractive for skeletal muscle gene therapy, as the large cargo capacity of HACs could provide a feasible solution to increase gene expression in myofibres. Skeletal myofibres are indeed syncitia containing several post-mitotic nuclei. Therefore, in the case of a recessive disease, the possibility to have one genetically corrected nucleus carrying more than one copy of the gene of interest could provide a way to decrease the number of cells to transplant, without decreasing the possible efficacy (effectively increasing gene dosage and safety). However, this approach is still limited to ex vivo correction, as direct HAC transfer in vivo faces the limitation of the presence of xenogeneic chromosomes from the donor cell line inside the microcells. Active research is currently on going to develop strategies that can overcome this limitation (Mitsuo Oshimura, personal communication).
Even though the HAC transfer is limited to ex vivo correction of stem/progenitor cells, the use of "clinicalfriendly" reagents and protocols will be critical to accelerate the possible clinical translation of this platform, which still relies on the use of chicken DT40 cells to engineer the HAC and rodent cells (CHO or mouse A9 cells) to generate microcells. CRISPR/Cas9 technology (Hsu et al. 2014 ) could be extremely valuable to avoid the need of homologous recombination in DT40 cells. Ad hoc approval of rodent cell lines to support generation of medicinal products for human cell therapy has already been successfully done for cornea and skin transplants (Mavilio et al. 2006; Rama et al. 2010 ) and could be a feasible ad interim solution for clinical translation of HACs. Another area of active studies concerns the delivery of corrected cells. Mesoangioblasts are currently delivered in the arterial circulation via femoral artery injection (mice) or catheterisation (humans). However, this still does not allow targeting of the diaphragm, heart, spinal muscles and muscles of the pelvic girdle (critical for ambulation). It is foreseeable that the rapidly evolving fields of interventional radiology and cardiology could supply technical advances and new devices that will overcome current limitations of cell delivery to dystrophic muscles.
Overall, the HAC pathway to clinical translation is not expected to be more difficult or challenging than that of other viral vectors (Narayanan et al. 2014) . Nevertheless, it is expected that the presence of a supernumerary (non-pathogenic) chromosome in cells candidate for a transplant will require stringent safety studies in large animal models. This scenario will also need to be considered in the context of a possible need for a mild immune suppression in Duchenne boys undergoing autologous transplants, as T cells primed to recognize dystrophin epitopes have been reported in a significant number of patients with DMD (approximately 20 % steroid-treated and 50 % steroid-naive) (Mendell et al. 2010a; Flanigan et al. 2013) .
In recent years, several gene repair/replacement strategies became available for DMD (Benedetti et al 2013) . Some of them, such as antisense oligonucleotidemediated exon skipping and the use of quasidystrophins, result in the generation of a shorter protein that should retain most of the functions of the full-length dystrophin. Even though exon skipping for DMD has been tested in phase III clinical trials (NCT01254019, www.clinicaltrials.gov), this remains a mutationspecific strategy, hence not applicable to large deletions and to mutations in strategic domains of the gene/ protein (Aartsma-Rus et al. 2009 ). Similar short-/quasi-dystrophins have been delivered to muscle using adeno-associated viral (AAV) vectors (Harper et al. 2002) . The immunological profile of AAV vectors is still a matter of active clinical investigation (Mendell et al. 2010a, b) as it is their integration safety profile (Schultz and Chamberlain 2008; Smith 2008; Kaeppel et al. 2013; Cogne et al. 2014) . A recent strategy based upon triple trans-splicing AAV vectors provides a possible solution to transfer the full-length dystrophin cDNA, thus overcoming the 4.7-kb single-AAV packaging capacity (Koo et al. 2014) . Nevertheless, another recent report shows that AAV vectors do not efficiently target muscle satellite stem cells in vivo, thus limiting their effect to post-mitotic myonuclei (assuming muscle tissue architecture is preserved) and not to the stem cell compartment (Arnett et al. 2014) . Transposons promise to deliver large genes efficaciously. They could accommodate the entire dystrophin cDNA (but not the entire locus) and, similarly to HACs, are not directly deliverable to muscle but limited to ex vivo gene correction (Di Matteo et al. 2012) . Although some transposon systems have been already manufactured under clinical-grade conditions (Singh et al. 2013 ) and should not require a clonal selection of the corrected cell population, efficacy and insertional mutagenesis in human cells following introduction of large genes, such as dystrophin, will need to be carefully evaluated in specific studies (Hackett et al. 2013) .
What is beyond DMD for HAC-mediated gene therapy? Certainly, the scenario is complex and the competing strategies are many (Naldini 2011) . Mutations in large genes other than dystrophin will benefit from the pre-clinical work conducted in DMD. An example of this could be in dysferlinopathies, a group of different autosomal recessive muscular dystrophies caused by mutations in the 55 exons long dysferlin gene, whose cDNA size (6.2 kb, not including expression-control elements) challenges the cloning capacity of viral vectors (Barthelemy et al. 2011) . Importantly, preclinical work has been done using muscle stem cell transplantation in a mouse model of dysferlynopathy . Diseases in tissues other than muscle could also be candidate for HAC-mediated gene therapy. This is particularly relevant for genes/loci requiring complex regulation, such as the globins and the relative haemoglobinopathies or for disorders of red blood cells such as recessive spherocytosis, where the mutated gene-alpha spectrin-is related to dystrophin in terms of evolution, size and function (Broderick and Winder 2005) . The deep knowledge on haematopoietic stem cell biology and transplantation would be a major plus for ex vivo gene therapy of this subset of disorders. Finally, the space on the HAC could also be exploited to accommodate more than one gene, different gene functions or several copies of the same gene, as was shown for factor VIII deficiency and haemophilia A (Kurosaki et al. 2011) .
Conclusions
The field of human artificial chromosome engineering has experienced considerable progress from its initial studies of gene function and animal transgenesis. HAC translational potential for gene therapy has been demonstrated for DMD, but several other disorders might be amenable to have a similar approach. It is possible that the active research in DMD and its critical need for a therapy will also accelerate technological advances to overcome current bottlenecks that prevent widespread use of this platform for gene replacement therapies.
Even though sometimes in life and science "less is more", we cannot ignore that in gene therapy size matters: hopefully HACs will be ready to address this issue in clinical trials in a not so distant future.
